ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

NCT03911505 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Pompe Disease (Late-onset)

Interventions

BIOLOGICAL: Cipaglucosidase Alfa
DRUG: Miglustat

Sponsor

Amicus Therapeutics